Each enteric-coated sustained-release capsule contains Rabeprazole 20 mg (Enteric Coated) + Domperidone BP 30 mg SR.

Rabiros-D Capsules combine Rabeprazole, a proton pump inhibitor (PPI), with Domperidone, a prokinetic agent, to provide comprehensive management of Gastroesophageal Reflux Disease (GERD). The formulation effectively suppresses gastric acid secretion while improving gastrointestinal motility and accelerating gastric emptying, helping relieve acid reflux symptoms and enhancing patient comfort.

Rabiros-D Capsules are indicated for the treatment of Gastroesophageal Reflux Disease (GERD).

Rabeprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly inhibiting the H⁺/K⁺-ATPase enzyme at the secretory surface of gastric parietal cells. Domperidone is a dopamine receptor antagonist (D1 and D2) that enhances gastrointestinal smooth muscle activity by facilitating acetylcholine release, promoting gastric emptying, increasing gastrointestinal motility, and reducing reflux symptoms.

The recommended dosage is one capsule once daily before food for 4–8 weeks, or as directed by the physician.

Rabiros-D Capsules are contraindicated in patients with known hypersensitivity to Rabeprazole, Domperidone, or any component of the formulation.